Pricing schemes for new drugs: A welfare analysis

Social Science and Medicine

Volumn 102, Issue , 2014, Pages 69-73

  Levaggi, Rosella ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Listing process; Pharmaceutical industry; Price regulation; Value based pricing; Welfare analysis

Indexed keywords

BARGAINING; DRUG; PHARMACEUTICAL INDUSTRY; PRICE DETERMINATION; PRICING POLICY; WELFARE ECONOMICS;

ARTICLE; CALCULATION; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG MARKETING; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; REIMBURSEMENT; WELFARE;

LISTING PROCESS; PHARMACEUTICAL INDUSTRY; PRICE REGULATION; VALUE BASED PRICING; WELFARE ANALYSIS;

COST CONTROL; COSTS AND COST ANALYSIS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS; ITALY; PHARMACEUTICAL PREPARATIONS; SOCIAL WELFARE;

EID: 84894228547     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2013.11.048     Document Type: Article

References (27)

1. Adamski J., Godman B., Ofierska-Sujkowska G., Osinska B., Herholz H., Wendykowska K., et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research 2010, 10:153.
2. Antonanzas F., Juarez-Castello C., Rodriguez-Ibeas R. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Economics, Policy and Law 2011, 6(3):391-403.
3. Appleby J., Devlin N., Parkin D., Buxton M., Chalkidou K. Searching for cost effectiveness thresholds in the NHS. Health Policy 2009, 91(3):239-245.
4. Bardey D., Bommier A., Jullien B. Retail price regulation and innovation: reference pricing in the pharmaceutical industry. Journal of Health Economics 2010, 29(2):303-316.
5. Barigozzi F., Levaggi R. Emotions in physician agency. Health Policy 2008, 88(1):1-14.
6. Barros P.P. The simple economics of risk sharing agreements between the NHS and the pharmaceutical industry. Health Economics 2011, 20(4):461-470.
7. Barros P.P., Levaggi R. Searching for approval: risk sharing as price discount?. Mimeo 2011.
8. Carone G., Schwierz C., Xavier A. Cost-containment policies in public pharmaceutical spending in the EU 2012, Technical report, European Commission-Economic and Financial Affairs.
9. Claxton K. OFT, VBP: QED?. Health Economics 2007, 16(6):545-558.
10. Claxton K., Briggs A., Buxton M., Culyer A., McCabe C., Walke S., et al. Value based pricing for NHS drugs: an opportunity not to be missed?. British Medical Journal 2008, 336:252-254.
11. Claxton K., Sculpher M., Carroll S. Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS 2011, Working papers 60, Centre for Health Economics, University of York.
12. Cook J., Vernon J., Mannin R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008, 26(7):551-556.
13. Danzon P.M., Towse A.K., Mestre-Ferrandiz J. Value-based differential pricing: Efficient prices for drugs in a global context 2012, Working papers 18593, National Bureau of Economic Research, Inc.
14. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003, 22(2):151-185.
15. Dulleck U., Kerschbamer R. On doctors, mechanics, and computer specialists: the economics of credence goods. Journal of Economic Literature 2006, 44(1):5-42.
16. Griffin S.C., Claxton K.P., Palmer S.J., Sculpher M.J. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Economics 2011, 20(2):212-224.
17. Jena A.B., Philipson T. Cost-effectiveness analysis and innovation. Journal of Health Economics 2008, 27(5):1224-1236.
18. Laffont J.-J., Tirole J. Atheory of incentives in procurement and regulation 1994, MIT Press.
19. Levaggi L., Levaggi R. Welfare properties of restrictions to health care based on cost effectiveness. Health Economics 2011, 20(1):101-110.
20. Lilico A. Risk sharing pricing models in the distribution of pharmaceuticals 2003, Staff working papers 2003.1, Europe Economics.
21. OECD Health at a glance 2011: OECD indicators 2011, OECD Publishing.
22. Pammolli F., Magazzini L., Riccaboni M. The productivity crisis in pharmaceutical R&D. Nature Review Drug Discovery 2011, 10(6):428-438.
23. Panos K., Taylor D., Manning J., Carr M. Implementing value-based pricing for pharmaceuticals in the UK 2010, 2020Health.
24. PhRMA Annual report 2011 2011, PhRMA.
25. Towse A., Garrison L. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk sharing agreements for innovative medical products. Pharmacoeconomics 2010, 28(2):93-102.
26. Zaric G.S., O'Brien B.J. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget. Health Economics 2005, 14(8):793-803.
27. Zaric G.S., Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value in Health 2009, 12(5):838-845.